Gelesis Revenue and Competitors
Estimated Revenue & Valuation
- Gelesis's estimated annual revenue is currently $15.8M per year.
- Gelesis's estimated revenue per employee is $188,214
- Gelesis's total funding is $312.8M.
Employee Data
- Gelesis has 84 Employees.
- Gelesis grew their employee count by -18% last year.
Gelesis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.8M | 73 | -39% | $107.3M | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $3.1M | 26 | 63% | N/A | N/A |
#4 | $29.6M | 125 | 18% | $351M | N/A |
#5 | $15.8M | 84 | -18% | $312.8M | N/A |
#6 | $0.5M | 7 | 17% | N/A | N/A |
#7 | $235M | 269 | -43% | $340.9M | N/A |
#8 | $2.2M | 28 | 4% | N/A | N/A |
#9 | $0.6M | 10 | -9% | N/A | N/A |
#10 | $0.5M | 9 | 29% | N/A | N/A |
What Is Gelesis?
Gelesis is a registrational-stage biotechnology company developing a novel category of first-in-class therapies for weight loss and GI-related diseases. Our platform uses a clinically validated hydrogel technology composed of naturally derived building blocks. The Gelesis portfolio includes a product for obesity and overweight and a pipeline with potential therapies for Non-alcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH), Type 2 diabetes and Chronic Idiopathic Constipation (CIC). Gelesis is headquartered in Boston, Mass. and was founded by PureTech Health and a group of leading obesity researchers. Gelesis is led by a strong management team, with expertise in medicine, materials science, manufacturing and commercialization. Our scientific advisory board and clinical advisors are leading experts in obesity and chronic disease. Community guidelines: http://bit.ly/2Q8VfUG
keywords:Biotechnology
$312.8M
Total Funding
84
Number of Employees
$15.8M
Revenue (est)
-18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Gelesis News
Gelesis' Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species...
Gelesis Holdings Inc (GLS) stock has risen 9.73% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.
The Company is evaluating and investigating its technology in GI-related diseases. Gelesis consummated a business combination with an SPAC in...
Gelesis announced today that leading U.S. direct-to-patient healthcare company Ro has placed a $30 million fully paid pre-order for the company’s first commercial product for weight management, Plenity®. Plenity was initially made available through a beta launch in 2020, and demand quickly outpa ...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, announced today that its Founded Entity, Gelesis, Inc. (“Gelesis”) received a $30 million fully paid pre-order for the company’s first commercial product for weight management, ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $14.6M | 84 | 5% | $189.2M |
#2 | $37.4M | 84 | -10% | N/A |
#3 | $16M | 84 | 4% | N/A |
#4 | $10.9M | 84 | 17% | N/A |
#5 | $16.3M | 84 | 18% | N/A |